Analyst Price Targets — RYTM
Latest News for RYTM
BOSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8 a.m. ET on Tuesday, May 5, 2026 to report its first quarter 2026 financial results and provide a corporate update.
SG Americas Securities LLC reduced its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 40.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,741 shares of the company's stock after selling 7,813 shares during the period. SG
-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers.
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
This little-known biotech company has a different strategy than the established weight-loss drug market leaders. But is it likely to be successful?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RYTM.
U.S. House Trading
No House trades found for RYTM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.